The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Spring 2025 RFA: Molecular MRI Biomarker Program, 2026Mapping Mitochondrial Dysfunction in Parkinson’s Disease Using 15N-Magnetic Resonance of Nicotinamide Metabolism (MiND15)
Study Rationale:
In Parkinson’s disease, one of the earliest problems in the brain is a failure of mitochondria—tiny structures that produce energy for cells. This energy failure happens before many...
-
Spring 2025 RFP: Accelerating Biological Understanding and Therapeutic Translation for PD- Biology, 2026Bidirectional Genome-wide CRISPRi/a Screening Using Ratiometric GCase Substrates to Identify Genetic Modulators of Lysosomal GCase Activity
Study Rationale:
Mutations in the gene GBA1, are the most common genetic risk factor for Parkinson Disease (PD). Mutations in GBA1 lead to malfunctioning of the protein glucocerebrosidase, which acts...
-
Spring 2025 RFP: Accelerating Biological Understanding and Therapeutic Translation for PD- Biology, 2026Deciphering Intracellular Pathways Altered by LRRK2 Kinase Activity and Phospho-RAB Effector Function
Study Rationale:
Gain-of-function mutations in LRRK2 cause familial Parkinson’s disease (PD) and increase the risk of developing the sporadic form of the disease. However, how...
-
Summer 2025 RFA: Personalized Approaches for Understanding, Assessing and Improving Gait in Parkinson’s Disease Research Program, 2026A Novel Digital Music-based Autonomous Personalized Walking Intervention to Improve Gait and Walking Automaticity in Parkinson Disease
Study Rationale:
People with Parkinson disease often take small, slow and unsteady steps, which makes it hard to get around and lowers their quality of life. While focusing on walking can help a little...
-
Fall 2025 RFP: Data Advice To Action - DATA-PD, 2026Blood-based Signatures of CSF Synuclein SAA Positivity
Study Rationale:
The ability to identify people during life, who are likely to have underlying Lewy body pathology has been a game-changer. However, the current test (SAA) is limited...
-
Research Grant, 2026From Functional Maps to Clinical Outcomes: Interpreting GBA1 Variant Effects in Parkinson's Disease
Study Rationale:
Genetic variants in the GBA1 gene are among the most important risk factors for Parkinson’s disease. GBA1 encodes an enzyme that breaks down waste inside lysosomes...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.